{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.390","upperLimit":"0.940","value":"0.727"},{"groupId":"OG001","lowerLimit":"0.664","upperLimit":"1.0","value":"1.0"},{"groupId":"OG002","lowerLimit":"0.366","upperLimit":"0.779","value":"0.583"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"24"}],"units":"Participants"}],"description":"CBR will be defined as the rate of patients with stable disease, partial response or complete response as their best response during treatment.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive pembrolizumab IV over 30 minutes and pemetrexed disodium IV over 10 minutes on day 1. Treatment with pembrolizumab repeats every 21 days for up to 35 cycles (2 years) in the absence of disease progression or unacceptable toxicity. Cycles of pemetrexed disodium repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients who had stable disease, partial response, or complete response after completion of 35 cycles of pembrolizumab, may continue pembrolizumab for an additional 17 cycles (1 year) in the absence of disease progression or unacceptable toxicity. Patients additionally undergo blood sample collection, CT, PET/CT or MRI and may also undergo PSMA PET on study.","id":"OG000","title":"Cohort A"},{"description":"Patients receive pembrolizumab IV over 30 minutes and pemetrexed disodium IV over 10 minutes on day 1. Treatment with pembrolizumab repeats every 21 days for up to 35 cycles (2 years) in the absence of disease progression or unacceptable toxicity. Cycles of pemetrexed disodium repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients who had stable disease, partial response, or complete response after completion of 35 cycles of pembrolizumab, may continue pembrolizumab for an additional 17 cycles (1 year) in the absence of disease progression or unacceptable toxicity. Patients additionally undergo blood sample collection, CT, PET/CT or MRI and may also undergo PSMA PET on study.","id":"OG001","title":"Cohort A1"},{"description":"Patients receive pembrolizumab IV over 30 minutes and pemetrexed disodium IV over 10 minutes on day 1. Treatment with pembrolizumab repeats every 21 days for up to 35 cycles (2 years) in the absence of disease progression or unacceptable toxicity. Cycles of pemetrexed disodium repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients who had stable disease, partial response, or complete response after completion of 35 cycles of pembrolizumab, may continue pembrolizumab for an additional 17 cycles (1 year) in the absence of disease progression or unacceptable toxicity. Patients additionally undergo blood sample collection, CT, PET/CT or MRI and may also undergo PSMA PET on study.","id":"OG002","title":"Cohort B (Non-adenoid Cystic Carcinoma)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"24 weeks","title":"Clinical Benefit Rate (CBR)","type":"PRIMARY","unitOfMeasure":"proportion of patients"}